Baldrige Asset Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Baldrige Asset Management’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$1K	Hold	23	–	–	﹤0.01%	333
2022 Q4	$1K	Hold	23	–	–	﹤0.01%	294
2022 Q3	$1K	Hold	23	–	–	﹤0.01%	287
2022 Q2	$0	Hold	23	–	–	﹤0.01%	306
2022 Q1	$1K	Hold	23	–	–	﹤0.01%	302
2021 Q4	$1K	Hold	23	–	–	﹤0.01%	316
2021 Q3	$1K	Hold	23	–	–	﹤0.01%	342
2021 Q2	$1K	Buy	+23	New	+$1.13K	﹤0.01%	340

Other funds holding BBC

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

DSC

Duncker Streett & Co St. Louis, Missouri $526M AUM 22.2% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Baldrige Asset Management's BBC Position: Q1 2023 in Review

Baldrige Asset Management held its Virtus Biotech Clinical Trials ETF (BBC) position steady in Q1 2023 at 23 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #333.

Baldrige Asset Management first reported a position in BBC in Q2 2021 and has held it in 8 quarters since. 16 funds tracked by Wall St. Rank hold BBC as of Q1 2023.

Baldrige Asset Management held 23 shares of Virtus Biotech Clinical Trials ETF worth $1K as of Q1 2023.
Baldrige Asset Management left its Virtus Biotech Clinical Trials ETF share count unchanged in Q1 2023.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #333 holding.
Baldrige Asset Management first reported a position in Virtus Biotech Clinical Trials ETF in Q2 2021 and has held it in 8 quarters since.
16 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.